← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 2005Last known activity
Jan 1, 2016
Acquired by Arbor Pharmaceuticals → Azurity on Jan 1, 2015
Timeline
1990s
- Jan 1, 1999
XenoPort, Inc.— Founded
2010s
- Jan 1, 2015
Arbor Pharmaceuticals— Acquired By
2020s
- Aug 24, 2021
Azurity— Now
Drugs by trial phase (16 distinct, 28 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Alcohol Drinking
- Alcoholism
- Diabetic Neuropathies
- Disease
- Dyssomnias
- Esophagitis, Peptic
- Gastroesophageal Reflux
- Headache
- Migraine Disorders
- Muscle Spasticity
- Neuralgia
- Neuralgia, Postherpetic
- Parasomnias
- Parkinson Disease
- Peripheral Nervous System Diseases
- Psoriasis
- Psychomotor Agitation
- Restless Legs Syndrome
- Sleep Wake Disorders
- Spinal Cord Injuries
- Syndrome
Recent trials (30)
- NCT02560766Lead sponsorPhase 4Jan 1, 2016
- NCT02633683Lead sponsorPhase 4Jan 1, 2016
- NCT02633657Lead sponsorPhase 1Jan 1, 2016
- NCT02424695CollaboratorPhase 4Jun 1, 2015
- NCT02252536CollaboratorPhase 2Jun 1, 2015
- NCT02173301Study directorPhase 2Jun 1, 2014
- NCT02173301Lead sponsorPhase 2Jun 1, 2014
- NCT01668667Lead sponsorPhase 4Jun 1, 2012
- NCT01516372Lead sponsorPhase 1Jan 1, 2012
- NCT01476124Lead sponsorPhase 1Aug 1, 2011
- NCT01411124Lead sponsorPhase 1Jun 1, 2011
- NCT01171313Study directorPhase 2Jul 1, 2010
- NCT01171313Lead sponsorPhase 2Jul 1, 2010
- NCT00978016Study directorPhase 2Sep 1, 2009
- NCT00914602Lead sponsorPhase 1/Phase 2May 1, 2009
Details
- Founded
- Santa Clara, CA, US Jan 1, 1999
- Last known activity
- Jan 1, 2016